Coveler Andrew L, Rossi Gabriela R, Vahanian Nicholas N, Link Charles, Chiorean E Gabriela
Department of Medicine/Division Oncology, University of Washington, Fred Hutchinson Cancer Research Center, 825 Eastlake Ave E, G4-833, Seattle, WA 98109-1023, USA.
NewLink Genetics, Ames, IA 50010, USA.
Immunotherapy. 2016 Feb;8(2):117-25. doi: 10.2217/imt.15.113. Epub 2016 Jan 20.
Pancreatic adenocarcinoma is the 4th leading cause of cancer death in the USA and the EU. A minority of patients presents with surgically resectable and potentially curable disease, but among these, 80% are destined to relapse and overall survival rates with adjuvant chemotherapy average 24 months. Immunotherapy is a promising therapeutic option and a potential paradigm shift in the treatment of patients with pancreatic cancer, and may be particularly effective when used early in the disease course to prevent metastatic spread. Algenpantucel-L (HyperAcute Pancreas, NewLink Genetics, Ames, IA, USA) is a whole-cell immunotherapy consisting of irradiated allogeneic pancreatic cancer cells genetically engineered to express the murine enzyme α-GT, which results in hyperacute rejection of the tumor cells with complement- and antibody-dependent cytotoxicity. Phase II clinical trial data has been encouraging, particularly for patients who demonstrated humoral immunologic responses. Here, we report preliminary results and biomarkers correlations with clinical activity of algenpantucel-L in pancreatic cancer.
胰腺腺癌是美国和欧盟癌症死亡的第四大主要原因。少数患者表现为可手术切除且有潜在治愈可能的疾病，但其中80%注定会复发，辅助化疗后的总体生存率平均为24个月。免疫疗法是一种有前景的治疗选择，可能会给胰腺癌患者的治疗带来潜在的模式转变，并且在疾病早期使用以预防转移扩散时可能特别有效。Algenpantucel-L（HyperAcute Pancreas，美国新链接遗传学公司，艾姆斯，爱荷华州）是一种全细胞免疫疗法，由经过辐射的同种异体胰腺癌细胞组成，这些细胞经过基因工程改造以表达鼠源酶α-GT，从而通过补体和抗体依赖性细胞毒性导致肿瘤细胞的超急性排斥反应。II期临床试验数据令人鼓舞，特别是对于表现出体液免疫反应的患者。在此，我们报告Algenpantucel-L在胰腺癌中的初步结果以及与临床活性相关的生物标志物。
